X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MTEM intends to use the net proceeds from the proceeds to fund its ongoing clinical studies, including MT-6402, a third generation engineered toxin body (ETB), capable of directly killing PD-L1 expressing tumor.
Lead Product(s): MT-6402
Therapeutic Area: Oncology Product Name: MT-6402
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: BVF Partners
Deal Size: $9.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 28, 2024
Details:
MT-8421 was designed to eliminate CTLA-4 expressing Tregs in the tumor microenvironment. It is being developed for patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.
Lead Product(s): MT-8421,Nivolumab
Therapeutic Area: Oncology Product Name: MT-8421
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
MTEM intends to use the net proceeds from the private placement to fund its ongoing clinical studies including, MT-6402, a third generation engineered toxin body (ETB) that consists of a single chain variable fragment (scFv) with affinity for PD-L1, for multiple solid tumors.
Lead Product(s): MT-6402
Therapeutic Area: Oncology Product Name: MT-6402
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Stifel
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 13, 2023
Details:
MT-0169 was designed to destroy CD38+ tumor cells through internalization of CD38 and FDA after reviewing safety data on the program, has removed the partial clinical hold on Phase 1 patient enrollment.
Lead Product(s): MT-0169
Therapeutic Area: Oncology Product Name: MT-0169
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
The FDA has asked MTEM to provide narratives on the two patients who experienced cardiotoxicity at 50 mcg/kg, justification for the revised dose of 5 mcg/kg, and data evaluating the clinical benefit-to-risk ratio seen with the lower doses of MT-0169, among other requests.
Lead Product(s): MT-0169
Therapeutic Area: Oncology Product Name: MT-0169
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2023
Details:
MT-8421 was designed to eliminate CTLA-4 expressing Tregs in the tumor microenvironment. It is being developed for patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.
Lead Product(s): MT-8421
Therapeutic Area: Oncology Product Name: MT-8421
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
Engineered toxin body targeting CTLA-4 (MT-8421) also depletes Tregs in the tumor microenvironment and synergizes with αPD-1 to enhance T cell immunity.
Lead Product(s): MT-8421
Therapeutic Area: Oncology Product Name: MT-8421
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
Presentations on the MT-6402 (PD-L1) and MT-5111(HER2) Phase I dose escalation programs demonstrated unique biology, continued tolerability, and dose-dependent pharmacodynamic effects.
Lead Product(s): MT-6402
Therapeutic Area: Oncology Product Name: MT-6402
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
MT-6402, a novel engineered toxin body targeting PD-L1,12 patient has been dosed, till date with two dose cohort, the pharmacodynamic effects including monocyte and myeloid-derived suppressor cell depletion and T cell activation have been observed in majority of patients.
Lead Product(s): MT-6402
Therapeutic Area: Oncology Product Name: MT-6402
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
MTEM announced the decision to discontinue development of MT-3724, MTEM’s only first-generation ETB. MTEM will focus on the clinical development of next-generation ETBs MT-5111, TAK-169, and MT-6402, as well as advancing next-generation preclinical ETB candidates.
Lead Product(s): TAK-169
Therapeutic Area: Oncology Product Name: TAK-169
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
